New targeted drug ZV0203 enters first human tests for Hard-to-Treat HER2 cancers
NCT ID NCT05423977
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug, ZV0203, in 36 adults with HER2-positive advanced solid tumors that have not responded to standard treatments. ZV0203 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to HER2-positive tumor cells. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZV0203 (an antibody-drug conjugate)
- What this could lead to
- If it works, this could point toward a new treatment option for people with HER2-positive advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 36 people, focused on safety and dosing. It is too soon to know if ZV0203 will shrink tumors or have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PKUCare Luzhong Hospital
Zigong, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.